This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry June 10, 2025 By Christopher Cole News Article The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond. Washington, DC, USA - June 24, 2022: The symbol of the U.S. BIO President and CEO John F.
Artificial intelligence addresses key limitations of traditional health technology assessments—such as data gaps and time-intensive processes—through automation, real-time data integration, and advanced predictive modeling, leading to faster and more informed decisions. AI supports personalized medicine and real-world evidence integration.
The NHC appreciates CMS’ efforts to gather patient-centered data as part of this ICR and its commitment to making the process more relevant for patients and patient organizations. While we acknowledge these improvements, it is important to note that some aspects of the data collection process may remain challenging.
I’ll expand a bit about two different genes that carry MTHFR variations, and I’ll break down the different test results and what they can mean, further down in the article. While we can’t change our genes, I can tell you that we can absolutely change their expression!
This morning, I read through Matt Stoller’s most recent article about Amazon. As I read the article, I thought to myself that “I’ve heard this story before.” 2) the pharmacy’s “usual and customary” price - the price they would charge outside of the insurance/PBM system.
We believe that patient-centric engagement is essential to ensure that the negotiation process leads to outcomes that genuinely benefit patients. Patient Engagement The NHC recognizes and commends CMS’ willingness to improve the listening sessions and the data submission processes. Improving the Data Collection (ICR) Process.
In some states, you can combine specialty and retail, but the retail operation is subject to the heavy policy and process requirements of specialty accreditation — which is an onerous burden for a retail pharmacy. Fortunately, those steps tend to be the least burdensome in the process.
In some states, you can combine specialty and retail, but the retail operation is subject to the heavy policy and process requirements of specialty accreditation — which is an onerous burden for a retail pharmacy. Fortunately, those steps tend to be the least burdensome in the process.
In this article, you will learn: What low dose naltrexone, or LDN, is How LDN benefits Hashimoto’s Potential side effects The Root Cause approach vs. conventional treatment Where to find LDN and how to take it What Is LDN? The first article was published in 2007, and it showed LDN as an effective and safe therapy for Crohn’s disease. [4]
In this article, ChatGPT weighs in on how pharmacists can use artificial intelligence. BCPS, BCIDP Article Posted 7 June 2023 With the exception of the questions in bold, this entire text was written by ChatGPT. Interview with: ChatGPT by OpenAI Interview by: Timothy P. Gauthier, Pharm.D.,
1 This trend underscores the importance of informed decision-making for those with chronic diseases and disabilities, who face crucial choices regarding their health care coverage – whether selecting between traditional Medicare and MA, choosing among MA plans, or navigating their selected plan to access necessary care. As of 2023, 30.8
In some states, you can combine specialty and retail, but the retail operation is subject to the heavy policy and process requirements of specialty accreditation — which is an onerous burden for a retail pharmacy. Fortunately, those steps tend to be the least burdensome in the process.
In this article, we’ll explore typical cases of healthcare companies using Salesforce, review the functionality of Salesforce CRM and the solutions for different sectors within life sciences and healthcare, and discover how Salesforce supports healthcare companies and communities. With Salesforce, they do it for 15 minutes.
24 Hours in the Hub Still Matters More June 16, 2025 By Chris Dowd, ConnectiveRx Commentary Article Pharmaceutical Commerce Pharmaceutical Commerce - June 2025 Volume 20 Issue 3 Doubling down on patient access and support fundamentals will win out over Washington’s next move. Future-Proofing Hubs is a Must.
June 18th 2025 Article The June issue of Pharmaceutical Commerce highlights the importance of embracing agility—and adaptable strategies—to better navigate industry challenges. Click here to view our interactive June 2025 issue! Related Content The Art of Agility Mike Hennessy Jr.
Expectation #2: Modification of sub-section(2)(b) of section 115BAB – Section 115BAB provides a concessional tax rate of 15 percent to the company that is engaged in the business of manufacturing or production of any article or thing and research in relation to, or distribution of, such article or thing manufactured or produced by it.
I should point out that the loopholes I’m about to describe have been closed in different ways over the last 10 years, which I’ll describe in my next article. Those patients would lose insurancecoverage/access to those products, but the PBM was contractually obligated to keep the product on formulary for the other 85% of lives.
They also experience some of the same problems that manufacturers and distributors face, like spotty tracking information due to the manual processes associated with barcode scanning of drugs. Jeff Webber Key Takeaways Real-world data enhances medication safety and supply chain efficiency. References 1. FDA at a Glance. Therapeutic Drug Use.
I wrote this article in hope that it serves as a starting point to help you determine which lab tests will be most helpful for uncovering your triggers. InsuranceCoverage/Interpretation : All of the thyroid tests listed above should be covered on insurance, if the practitioner who orders them is an MD, DO, PA or NP.
1 There are specific diseases—including hemophilia and sickle cell disease (SCD)—that are more widespread in groups enrolled in Medicaid than commercially insured individuals, due to the program’s concentration on children, disabled adults, and those families financially impacted by treatment costs. of average manufacturer price.
SHOW MORE Pharmacists can help oversee the treatment process to ensure patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are adhering to tafamidis. Because] insurance and cost barriers can be difficult for patients, pharmacists can help patients navigate copayment programs and the prior authorization process.”
In the past week, no less than three articles have called attention to the restrictions drug manufacturers have imposed to evade their legal responsibility to honor 340B program prescription discounts — as well as the impact those restrictions have had on 340B-eligible nonprofit entities’ ability to serve their patients and communities.
The first one was introduced on September 13, 2020, near the end of Trump’s first term, but was shut down by a federal judge due to the administration’s failure to comply with the proper implementation processes. Second, it does not address the core issues of higher prices, such as the use of rebates by insurers.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content